Sugi Predict

Sugi Predict / Compounds / SCHEMBL207440

SCHEMBL207440

SCHEMBL207440

COc1ccc(C=O)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.59
▸ ALDH1A1 P00352 4/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ TUBB4A P04350 1/20 0.53
▸ TUBB P07437 1/20 0.53
▸ TUBA3C P0DPH7 1/20 0.53
▸ TUBA1B P68363 1/20 0.53
▸ TUBA4A P68366 1/20 0.53
▸ TUBB4B P68371 1/20 0.53
▸ TUBB3 Q13509 1/20 0.53
▸ TUBB2A Q13885 1/20 0.53
▸ TUBB8 Q3ZCM7 1/20 0.53
▸ TUBA3E Q6PEY2 1/20 0.53
▸ TUBA1A Q71U36 1/20 0.53
▸ TUBA1C Q9BQE3 1/20 0.53
▸ TUBB6 Q9BUF5 1/20 0.53
▸ TUBB2B Q9BVA1 1/20 0.53
▸ TUBB1 Q9H4B7 1/20 0.53
▸ IDH1 O75874 3/20 0.50
▸ FDPS P14324 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501241 1.00 KDM4E (0.59) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL13568538 0.88 CYP11B1 (0.50) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL25281866 0.86 KDM4E (0.54) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL30385228 0.86 KDM4E (0.54) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL6213489 0.85 MKNK1 (0.57) KDM4EALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL27676255 0.83 TUBB4A (0.53) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL12252457 0.83 KDM4E (0.44) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL8016820 0.82 KDM4E (0.77) KDM4EALDH1A1L3MBTL1FDPSCYP2A6
SCHEMBL17541178 0.82 KDM4E (0.47) KDM4EALDH1A1L3MBTL1TUBB4ATUBB
SCHEMBL933951 0.82 KDM4E (0.57) KDM4EALDH1A1L3MBTL1FDPSCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084053-A1 3-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND King Faisal University (SA) 2025-03-13 — — US claimed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 — — CN claimed
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 — — CN claimed
US-11998545-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2024-06-04 — — US claimed
US-11932619-B1 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound King Faisal University (SA) 2024-03-19 — — US claimed
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 — — US claimed
US-11807651-B2 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile LOXO ONCOLOGY INC. (US) 2023-11-07 — — US claimed
US-20230212193-A1 CRYSTALLINE RET INHIBITOR ELI LILLY AND COMPANY 2023-07-06 — — US claimed
CN-111263760-B Method for preparing a compound 奥瑞生物药品公司 2023-06-23 — — CN claimed
EP-3694853-B1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE ARRAY BIOPHARMA INC (US) 2023-05-17 — — EP claimed
US-20200308194-A1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE LOXO ONCOLOGY, INC. 2020-10-01 — — US claimed
EP-3694853-A1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE Array BioPharma Inc. (US) 2020-08-19 — — EP claimed
US-10745419-B2 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile LOXO ONCOLOGY INC. (US) 2020-08-18 — — US claimed
CN-110878043-B Synthetic method of intermediate 6-methoxypyridine-3-formaldehyde of antihypertensive drugs of dipine class 南京哈柏医药科技有限公司 2020-08-14 — — CN claimed
CN-110878043-A Simple and convenient 6-methoxypyridine-3-formaldehyde synthesis process 南京哈柏医药科技有限公司 2020-03-13 — — CN claimed
WO-2019075092-A1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE EARY CHARLES TODD (US) 2019-04-18 — — WO claimed
US-20190106438-A1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE LOXO ONCOLOGY, INC. 2019-04-11 — — US claimed
CN-106800531-B A kind of fluorescence probe PMPA and the preparation method and application thereof 山西大学 2019-04-05 — — CN claimed
US-10092786-B2 Fire extinguishing composition comprising aldoketones compound XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) 2018-10-09 — — US claimed
US-20160332016-A1 Fire Extinguishing Composition Comprising Aldoketones Compound NANO FIRE, LLC 2016-11-17 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212193-A1 CRYSTALLINE RET INHIBITOR RET, BRAF, UACA KDM4E 1975/4885ALDH1A1 3682/4885L3MBTL1 1542/4885
US-11807651-B2 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile HCN2, REN, CYP2D6 KDM4E 263/4885ALDH1A1 259/4885L3MBTL1 4846/4885
US-20200308194-A1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE HCN2, REN, CYP2D6 KDM4E 263/4885ALDH1A1 259/4885L3MBTL1 4846/4885
US-11932619-B1 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound MCL1, NCL, DCK KDM4E 513/4885ALDH1A1 1482/4885L3MBTL1 1201/4885
US-20190106438-A1 PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE HCN2, REN, CYP2D6 KDM4E 263/4885ALDH1A1 259/4885L3MBTL1 4846/4885
US-10745419-B2 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile HCN2, REN, CYP2D6 KDM4E 263/4885ALDH1A1 259/4885L3MBTL1 4846/4885
US-20250084053-A1 3-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND MCL1, NCL, DCK KDM4E 513/4885ALDH1A1 1482/4885L3MBTL1 1201/4885
US-11998545-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF KDM4E 889/4885ALDH1A1 2868/4885L3MBTL1 1445/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF KDM4E 889/4885ALDH1A1 2868/4885L3MBTL1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.